IN2014KN02740A - - Google Patents
Info
- Publication number
- IN2014KN02740A IN2014KN02740A IN2740KON2014A IN2014KN02740A IN 2014KN02740 A IN2014KN02740 A IN 2014KN02740A IN 2740KON2014 A IN2740KON2014 A IN 2740KON2014A IN 2014KN02740 A IN2014KN02740 A IN 2014KN02740A
- Authority
- IN
- India
- Prior art keywords
- hiv
- provides
- polypeptidestabilized
- polypeptideor
- conformation
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261661050P | 2012-06-18 | 2012-06-18 | |
| PCT/EP2013/062553 WO2013189901A1 (en) | 2012-06-18 | 2013-06-17 | Stabilized gp120 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014KN02740A true IN2014KN02740A (enExample) | 2015-05-08 |
Family
ID=48628698
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2740KON2014 IN2014KN02740A (enExample) | 2012-06-18 | 2013-06-17 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20150183835A1 (enExample) |
| EP (1) | EP2861249A1 (enExample) |
| JP (1) | JP2015521592A (enExample) |
| KR (1) | KR20150023735A (enExample) |
| CN (1) | CN104619338A (enExample) |
| AU (1) | AU2013279456A1 (enExample) |
| CA (1) | CA2876762A1 (enExample) |
| IL (1) | IL235898A0 (enExample) |
| IN (1) | IN2014KN02740A (enExample) |
| MX (1) | MX2014014682A (enExample) |
| RU (1) | RU2015101081A (enExample) |
| SG (1) | SG11201407995RA (enExample) |
| WO (1) | WO2013189901A1 (enExample) |
| ZA (1) | ZA201408840B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10400015B2 (en) | 2014-09-04 | 2019-09-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant HIV-1 envelope proteins and their use |
| US10010605B2 (en) * | 2014-09-23 | 2018-07-03 | Merial, Inc. | FMDV recombinant vaccines and uses thereof |
| US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| EP3426291A1 (en) | 2016-03-09 | 2019-01-16 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Recombinant hiv-1 envelope proteins and their use |
| MX2019004681A (es) | 2016-10-21 | 2019-10-07 | Altor Bioscience Corp | Moleculas basadas en il-15 multimericas. |
| EP3697440A1 (en) | 2017-10-16 | 2020-08-26 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Recombinant hiv-1 envelope proteins and their use |
| CN109851664A (zh) * | 2017-11-30 | 2019-06-07 | 清华大学 | 一种基于抗体反向表位设计的蛋白质及其在制备抗艾滋病病毒疫苗中的应用 |
| MX2020013621A (es) | 2018-06-19 | 2021-03-25 | Nantcell Inc | Composiciones y metodos de tratamiento de vih. |
| WO2021249013A1 (en) * | 2020-06-10 | 2021-12-16 | Sichuan Clover Biopharmaceuticals, Inc. | Vaccine compositions, methods, and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2786488B1 (fr) * | 1998-11-27 | 2003-04-25 | Orstom | Mutants de la gp120 et leurs applications biologiques |
| WO2001000648A1 (en) * | 1999-06-25 | 2001-01-04 | Progenics Pharmaceuticals, Inc. | Stabilized viral envelope proteins and uses thereof |
| JP2010536885A (ja) * | 2007-08-24 | 2010-12-02 | ノバルティス アーゲー | Ｖ３ループに改変を有するｈｉｖｅｎｖタンパク質 |
| US9175070B2 (en) * | 2009-09-25 | 2015-11-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to HIV-1 and their use |
-
2013
- 2013-06-17 US US14/408,466 patent/US20150183835A1/en not_active Abandoned
- 2013-06-17 AU AU2013279456A patent/AU2013279456A1/en not_active Abandoned
- 2013-06-17 MX MX2014014682A patent/MX2014014682A/es unknown
- 2013-06-17 EP EP13729364.3A patent/EP2861249A1/en not_active Withdrawn
- 2013-06-17 CA CA2876762A patent/CA2876762A1/en not_active Abandoned
- 2013-06-17 JP JP2015516648A patent/JP2015521592A/ja active Pending
- 2013-06-17 CN CN201380032027.2A patent/CN104619338A/zh active Pending
- 2013-06-17 IN IN2740KON2014 patent/IN2014KN02740A/en unknown
- 2013-06-17 KR KR20157000850A patent/KR20150023735A/ko not_active Withdrawn
- 2013-06-17 RU RU2015101081A patent/RU2015101081A/ru not_active Application Discontinuation
- 2013-06-17 WO PCT/EP2013/062553 patent/WO2013189901A1/en not_active Ceased
- 2013-06-17 SG SG11201407995RA patent/SG11201407995RA/en unknown
-
2014
- 2014-11-25 IL IL235898A patent/IL235898A0/en unknown
- 2014-12-02 ZA ZA2014/08840A patent/ZA201408840B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150023735A (ko) | 2015-03-05 |
| AU2013279456A1 (en) | 2014-12-18 |
| SG11201407995RA (en) | 2015-01-29 |
| WO2013189901A1 (en) | 2013-12-27 |
| IL235898A0 (en) | 2015-01-29 |
| ZA201408840B (en) | 2016-08-31 |
| JP2015521592A (ja) | 2015-07-30 |
| CA2876762A1 (en) | 2013-12-27 |
| MX2014014682A (es) | 2015-03-04 |
| US20150183835A1 (en) | 2015-07-02 |
| CN104619338A (zh) | 2015-05-13 |
| RU2015101081A (ru) | 2016-08-10 |
| EP2861249A1 (en) | 2015-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2014014682A (es) | Glicoproteina 120 (gp120) estabilizada. | |
| CY1124043T1 (el) | Εξουδετερωτικα αντισωματα του ανθρωπινου ιου της ανοσοανεπαρκειας και μεθοδοι χρησης αυτων | |
| WO2013006688A3 (en) | N-terminal deleted gp120 immunogens | |
| EA201290956A1 (ru) | Вакцина против вич | |
| NZ709260A (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
| WO2013085550A3 (en) | V1v2 immunogens | |
| EA201891186A1 (ru) | Антитела, нейтрализующие вирус иммунодефицита человека | |
| PH12015501156A1 (en) | Pharmaceutical compositions | |
| WO2013016468A3 (en) | Compositions and methods for improving potency and breadth or hiv antibodies | |
| AU2015296298A8 (en) | Flagellin-based agents and uses including effective vaccination | |
| TR201909152T4 (tr) | Polisiklik-karbamoilpiridon bileşikleri ve bunların farmasötik kullanımı. | |
| PH12013502442A1 (en) | Inactivated dengue virus vaccine | |
| PH12015500274A1 (en) | Alkylpyrimidine derivatives for the treatment of viral infections and further diseases | |
| IN2015DN03202A (enExample) | ||
| WO2011106100A3 (en) | Method of inducing the production of protective anti-hiv-1 antibodies | |
| WO2014160747A3 (en) | Compositions and methods for the treatment or prevention of human immunodeficiency virus infection | |
| IN2014CH00395A (enExample) | ||
| EA201790495A1 (ru) | Фармацевтические композиции длительного действия | |
| UA118542C2 (uk) | Імуногенна сполука, що включає пептид gp41 віл, зв'язаний з білком-носієм crm197 | |
| ZA201307069B (en) | Combined cell based gp96-ig-siv/hiv, recombinant gp120 protein vaccination for protection from siv/hiv | |
| WO2015086738A3 (en) | Hiv vaccine | |
| AU2013235442A8 (en) | Stable peptide mimetics of the HIV-1 gp41 pre-hairpin intermediate | |
| IN2014DN09445A (enExample) | ||
| WO2012139097A3 (en) | Method of inducing neutralizing antibodies to human immunodeficiency virus | |
| WO2014210082A3 (en) | Camptothecin derivatives as anti-hiv agents and methods of identifying agents that disrupt vif self-association |